Jerry S.H. Lee, Ph.D.

Health Sciences Director, National Cancer Institute at the
National Institutes of Health

Dr. Lee serves as the Deputy Director of the National Cancer Institute’s (NCI) Center for Strategic Scientific Initiatives (CSSI) within the NCI Office of the Director.  In this role, he provides leadership and input in planning, developing, and implementing rapid strategic scientific and technology initiatives that keep the Institute ahead of the scientific curve with respect to potential new exciting areas and discoveries. This may involve direct development and application of advanced technologies, creation of new trans-disciplinary teams, and/or use of available federal mechanisms to forge novel partnerships that emphasize innovation and convergence of scientific disciplines. 

Specifically, Dr. Lee is responsible for scientific, programmatic, and operational oversight of CSSI’s broad scientific portfolio (~$190.2 million in FY12) carried out by more than 40 staff members within offices that include the Office of Cancer Nanotechnology Research (OCNR), Office of Cancer Clinical Proteomics Research (OCCPR), and the Office of Physical Sciences-Oncology (OPSO). Programs developed and launched to date by Center staff includes the Innovation Molecular Analysis Technologies (IMAT), the NCI Alliance for Nanotechnology in Cancer, The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Physical Sciences-Oncology Centers (PS-OC), Provocative Questions (PQ), and Cancer Target Discovery and Development (CTD2) network. These exploratory initiatives focus on the integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation of publicly available, broadly accessible, multi-dimensional data, knowledge, and tools to empower the entire cancer research continuum for patient benefit.

Prior to joining the NCI, Dr. Lee’s research experience involved elucidating mechanisms of age-related diseases by combining cell biology, molecular biology, and engineering approaches to understand various cellular reactions to external stimuli. He has co-authored over a dozen papers, four book chapters, and one book on the role of Rho GTPase-mediated nuclear and cellular mechanical responses to fluid flow and 3D culture and demonstrated their potential impact in diseases such as progeria and cancer.  He continues to advance understanding in this area by serving as adjunct assistant professor at Johns Hopkins University, where he earned his bachelor's degree in biomedical engineering and Ph.D. degree in chemical and biomolecular engineering. Dr. Lee also holds an appointment at the Department of Veterans Affairs (VA) Medical Center, Washington D.C. as a research health scientist collaborating with clinicians on patient-centered outcomes research through analysis of existing VA datasets. He is an active member of the American Association for Cancer Research (AACR), Biophysical Society, American Society of Mechanical Engineers (ASME), American Society for Cell Biology, Tau Beta Pi, and the Innovation Policy Forum of the National Academies Board on Science, Technology, and Economic Policy.